• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $715 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-139 Mln

Lyell Immunopharma Inc (LYEL) Share Price

$2.61

As on 04-Mar-2024 13:41 EST

up-down-arrow $-0.46-15.13%

  • Prev Close info

    $3.07

  • Day's Openinfo

    $3.11

  • Today's Highinfo

    $3.26

  • Today's Lowinfo

    $2.57

  • Today's Volumeinfo

    521,057

  • 52 Week rangeinfo

    $1.32 - 3.97

Please wait...

Lyell Immunopharma Inc (LYEL) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Lyell Immunopharma Inc (LYEL)
34.31 45.56 36.42 17.37 -- -- --
S&P BSE Sensex
2.26 2.48 9.47 23.51 12.82 15.42 13.43
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 04-Mar-2024  |  #As on 26-Oct-2023
2023
2022
Lyell Immunopharma Inc (LYEL)
-44.09 -55.17
S&P Small-Cap 600
13.89 -17.42
S&P BSE Sensex
18.74 4.44

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Lyell Immunopharma Inc (LYEL) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Lyell Immunopharma Inc (LYEL)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Lyell Immunopharma Inc (LYEL)

        Founder & Executive Chairman

        Dr. Richard D. Klausner M.D.

        President, CEO & Director

        Dr. Lynn Seely M.D., Ph.D.

        Headquarters

        South San Francisco, CA

        FAQs for Lyell Immunopharma Inc (LYEL)

        The total asset value of Lyell Immunopharma Inc (LYEL) stood at $ 830 Mln as on 30-Sep-23

        The share price of Lyell Immunopharma Inc (LYEL) is $2.61 (NASDAQ) as of 04-Mar-2024 13:41 EST. Lyell Immunopharma Inc (LYEL) has given a return of 17.37% in the last 1 years.

        Lyell Immunopharma Inc (LYEL) has a market capitalisation of $ 715 Mln as on 29-Feb-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Lyell Immunopharma Inc (LYEL) is 1.03 times as on 29-Feb-2024, a -0.65% premium to its peers’ median range of 2.98 times.

        Since, TTM earnings of Lyell Immunopharma Inc (LYEL) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Lyell Immunopharma Inc (LYEL) and enter the required number of quantities and click on buy to purchase the shares of Lyell Immunopharma Inc (LYEL).

        Lyell Immunopharma, Inc., a clinical-stage cell therapy company, engages in developing T-cell reprogramming technologies for patients with solid tumors. It develops therapies using an ex vivo genetic reprogramming technologies, such as c-Jun overexpression and NR4A3 gene knockout, to endow resistance to T-cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi-R to generate population of T cells with durable stemness, and Stim-R, a proprietary synthetic cell mimetic. The company's pipeline includes LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T-cell product candidate for the treatment of various solid tumors; LYL845, an epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate that targets multiple solid tumors; LYL119, a CAR T-cell product candidate for enhanced cytotoxicity. The company was incorporated in 2018 and is headquartered in South San Francisco, California. Address: 201 Haskins Way, South San Francisco, CA, United States, 94080

        The CEO & director of Dr. Richard D. Klausner M.D.. is Lyell Immunopharma Inc (LYEL), and CFO & Sr. VP is Dr. Lynn Seely M.D., Ph.D..

        The promoters of Lyell Immunopharma Inc (LYEL) have pledged 0% of the total equity as on Sep-23.

        Lyell Immunopharma Inc (LYEL) Ratios
        Return on equity(%)
        -33.07
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Lyell Immunopharma Inc (LYEL) was $-139 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $715.31 Mln
        • Revenue (TTM)revenue-information $0.17 Mln
        • Earnings (TTM) earning-information $-139.25 Mln
        • Cash date-information $575.43 Mln
        • Total Debt info $58.58 Mln
        • Insider's Holding 15.73%
        • Liquidity liquidity High
        • 52 Week range week-range $1.32 - 3.97
        • Shares outstanding share-outstanding 251,868,992
        • 5 Years Aggregate:

          CFO: $-580.53 Mln

          EBITDA: $-638.28 Mln

          Net Profit: $-800.14 Mln

        About The Company

        • IPO Date 17-Jun-2021
        • Founder & Executive Chairman Dr. Richard D. Klausner M.D.
        • President, CEO & Director Dr. Lynn Seely M.D., Ph.D.
        • Listing key-listing NASDAQ: LYEL
        • Country United States
        • Headquarters headquarters South San Francisco, CA
        • Website website https://www.lyell.com
        • Business

          Lyell Immunopharma, Inc., a clinical-stage cell therapy company, engages in developing T-cell reprogramming technologies for patients with solid tumors. It develops therapies using an ex vivo genetic reprogramming technologies, such as c-Jun...  overexpression and NR4A3 gene knockout, to endow resistance to T-cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi-R to generate population of T cells with durable stemness, and Stim-R, a proprietary synthetic cell mimetic. The company's pipeline includes LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T-cell product candidate for the treatment of various solid tumors; LYL845, an epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate that targets multiple solid tumors; LYL119, a CAR T-cell product candidate for enhanced cytotoxicity. The company was incorporated in 2018 and is headquartered in South San Francisco, California. Address: 201 Haskins Way, South San Francisco, CA, United States, 94080  Read more

        share-fund-plan-icon